Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
Tumor necrosis factor alpha (TNF-α) inhibitors reduce the production or signaling of a central inflammatory cytokine. In 1975 an endotoxin-induced serum factor that causes necrosis of tumors was described and named tumor necrosis factor. Cloning of human TNF in 1984 revealed a precursor related to lymphotoxin. Through its two receptors, TNF-α activates nuclear factor kappa B (NF-κB) and cell death pathways. Etanercept is a soluble receptor fusion protein that binds the cytokine, and C 87 is a small-molecule TNF-α inhibitor. In 1991 thalidomide was shown to inhibit TNF-α production by stimulated human monocytes, and its analogs lenalidomide and pomalidomide are also listed. Pathway compounds include the NF-κB inhibitor QNZ and necrostatin-1, an inhibitor of receptor-interacting protein kinase 1 (RIPK1).
Synonyms: TNF-α Antagonist III
R-7050 (TNF-α Antagonist III) is a tumor necrosis factor receptor (TNFR) antagonist with greater selectivity toward TNFα.
IDT is a TNFα modulator that targets and regulates the innate immune response. It has demonstrated significant efficacy in reducing paired helical filament tau and fibrillar amyloid accumulation, as well as enhancing the infiltration of neutrophils while decreasing TNFα expression within this population. IDT is a valuable reagent for research focused on Alzheimer’s disease and the underlying mechanisms of neuroinflammation.
Synonyms: H-TL1
Hydrostatin-TL1 is a nine-amino-acid peptide that serves as a TNF-α antagonist. By competitively inhibiting the interaction between TNF-α and its receptor TNFR1, Hydrostatin-TL1 reduces TNF-α-mediated cytotoxicity and inflammation. This peptide is valuable for research into TNF-α-associated inflammatory diseases, including rheumatoid arthritis, osteoporosis, and inflammatory bowel disease (IBD).
Out of stock
All 3 sizes